Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imeroprubart · 1 trial · 1 indication
Relapse is defined as a worsening (increase) of ≥ 1 point on the adjusted inflammatory neuropathy cause and treatment (aINCAT) score at any time point relative to Period 1 Baseline.
| Arm | Type | Description |
|---|---|---|
| Imeroprubart | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Imeroprubart | DRUG | Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2) |
| Placebo | DRUG | Matching placebo SC QW for 24 weeks (Period 1) |
Inclusion Criteria: * Have met clinical diagnostic criteria for typical CIDP (including incomplete typical CIDP) or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of...
Imeroprubart is an investigational small molecule being developed for chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Imeroprubart targets the neonatal Fc receptor (FcRn). By binding to FcRn, it is designed to reduce circulating IgG antibodies, which are implicated in the pathogenesis of CIDP. This mechanism is being evaluated in clinical trials for its potential to treat the condition.
Imeroprubart is being developed by Immunovant, Inc., a biopharmaceutical company. Immunovant is publicly traded on the Nasdaq under the ticker symbol IMVT.
Imeroprubart is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies and is still undergoing clinical trials to assess its safety and efficacy in patients with CIDP.
Imeroprubart is being evaluated in a Phase 2 clinical trial with the identifier NCT07032662. This randomized, double-blind, placebo-controlled study is recruiting approximately 162 adult participants with CIDP across multiple countries, including the United States and several European nations.